CYLERT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jan 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLERT is an oral tablet small-molecule NDA approved by Abbott in 1975 for management of attention and behavioral disorders. The exact mechanism of action and therapeutic indications are not specified in available data. This legacy product represents a mature, well-established therapeutic option in its category.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals a shrinking commercial team and shift toward maintenance mode rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYLERT presents limited career growth opportunity due to approaching LOE and zero linked job postings. This is a maintenance-mode asset best suited for early-career professionals seeking stability or those consolidating multiple legacy brands rather than high-impact career progression.
Brand ManagerField Sales
Worked on CYLERT at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.